Skip to main content


Fig. 2 | Clinical and Translational Allergy

Fig. 2

From: Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies

Fig. 2

Change in MOS-Sleep Scale, SPI-II score: a ASTERIA I, b ASTERIA II, and c GLACIAL. Arrows represent omalizumab dosing. Low numbers represent good quality sleep. Least-squares means were derived from a repeated-measures model adjusted for baseline value (less than median, greater than or equal to median) and baseline weight (<80, ≥80 kg). *p < 0.05; **p < 0.001; ***p < 0.01, versus placebo. MOS-Sleep Scale Medical Outcomes Study Sleep Scale, SPI-II Sleep Problem Index II

Back to article page